Zevra Therapeutics, Inc. — Income Charts
8 quarters of history · ending 2025-12-31 · SEC EDGAR
Source:10-K · 10-Q
Revenue, Gross Profit, Operating Income & Net Income
Margin (%)
Operating Expenses
Income Breakdown
Revenue↑+183.4% +$22M
$34M
Cost of Revenue↑+11.3% +$154K
$2M
R&D↓-68.6% -$6M
$3M
SG&A↑+26.2% +$4M
$20M
D&A↓-78.0% -$1M
$362K
Operating Income↑+115.2% +$31M
$4M
EBITDA↓-78.0% -$1M
$362K
Interest Expense↓-11.2% -$246K
$2M
Other Income/Expense↑+14.9% +$538K
$-3M
Pretax Income
$13M
Tax Provision↓-96.7% -$15M
$501K
Net Income
$12M
Operating Margin↑+754.9pts
15.9%
Net Margin
35.6%
Effective Tax Rate
4.0%
ETR (Continuing Operations)↑+21.0pts
4.0%
ETR Federal Statutory↑+0.0pts
21.0%
ETR State + Local (pp)↓-0.7pts
0.1%
ETR Foreign Differential (pp)
0.0%
Operating Lease Cost
$135K
Revenue YoY Variation↑+190.1pts
183.4%
Income YoY Variation↑+192.9pts
115.2%
Revenue QoQ Variation↓-195.0pts
30.9%
Income QoQ Variation↑+120.6pts
105.8%